In addition to CTLA-4 and PD-1, other immune checkpoints have arisen as potential targets of agonism and antagonism by mAbs including cell surface molecules whose stimulation promotes an anti-tumor T cell response such as CD40, and those, such as LAG-3, whose inhibition circumvents down-regulation of the cellular immune response when the body most needs it. Here, LAG3 is linked to neoplasm.